Seek Returns

A vs. LLY: Agilent vs. Eli Lilly Stock Comparison

How do Agilent (A) and Eli Lilly (LLY) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and Eli Lilly (LLY) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while LLY is classified in Pharmaceuticals.

Company profile comparison for Agilent (A) and Eli Lilly (LLY)
Profile ItemALLY
NameAgileThought, Inc. Class A Common StockEli Lilly and Company
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization49.28 billion USD1,206.07 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateNovember 18, 1999June 1, 1972
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

A
LLY
GSPC
Loading price history…
Agilent (A) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Agilent (A) and Eli Lilly (LLY). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Agilent (A) and Eli Lilly (LLY). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and Eli Lilly (LLY)
MetricALLY
Total Return (1Y)22.92%52.36%
Total Return (3Y, Annualized)19.33%34.18%
Total Return (5Y, Annualized)3.03%41.08%

Risk Profile

Drawdown History

A
LLY
GSPC
Loading price history…
Agilent (A) vs. Eli Lilly (LLY), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Agilent (A) and Eli Lilly (LLY). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and Eli Lilly (LLY)
MetricALLY
Volatility (1Y, Annualized)33.10%35.34%
Beta (5Y)1.220.40
Max Drawdown (5Y)-38.09%-34.48%
Avg. Volume (3M)2.25M2.52M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
A and LLY are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and Eli Lilly (LLY)
MetricALLY
Sharpe Ratio (1Y)0.561.36
Sortino Ratio (1Y)0.962.29

Profitability

ROE (TTM)

Both Agilent (A) at 20.97% and Eli Lilly (LLY) at 86.02% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max
109.18%
A
20.97%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

86.02%

Max
109.18%
LLY
86.02%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Agilent (A) at 19.53% and Eli Lilly (LLY) at 31.90% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A
19.53%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

31.90%

LLY
31.90%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and Eli Lilly (LLY) at 53.66% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max
83.12%
A
25.56%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

53.66%

Max
83.12%
LLY
53.66%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and Eli Lilly (LLY)
MetricALLY
ROE (TTM)20.97%86.02%
ROA (TTM)8.63%21.06%
Net Margin (TTM)19.53%31.90%
Operating Margin (TTM)25.56%53.66%
Gross Margin (TTM)53.65%83.63%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and Eli Lilly (LLY) at 44.70% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their Revenue Growth across different time periods.

EPS Growth

Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while Agilent (A) at 3.16% is closer to the peer norm — faster per-share earnings growth for LLY.

Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and Eli Lilly (LLY)
MetricALLY
Revenue Growth (YoY)6.73%44.70%
Revenue Growth (3Y CAGR)0.48%31.69%
EPS Growth (YoY)3.16%95.99%
EPS Growth (3Y CAGR)3.02%51.71%

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and Eli Lilly (LLY) at 1.39 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
A
2.05
Min
0.10

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.39

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
LLY
1.39
Min
0.10
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Agilent (A) at 0.56 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.23 uses more debt funding than most peers.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max
1.42
Q3
0.65
A
0.56
Median
0.15
Q1
0.02
Min
0.00

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.23

Max
1.42
LLY
1.23
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and Eli Lilly (LLY)
MetricALLY
Current Ratio (MRQ)2.051.39
Debt / Equity (MRQ)0.561.23
Net Debt / EBITDA1.150.96

Dividends

Dividend Yield (TTM)

Both Agilent (A) at 0.59% and Eli Lilly (LLY) at 0.49% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A
0.59%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.49%

LLY
0.49%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Both Agilent (A) at 19.98% and Eli Lilly (LLY) at 21.71% pay out more of their earnings than any of their industry peers — the thinnest cover in their groups, so dividend headroom deserves attention.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A
19.98%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.71%

LLY
21.71%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and Eli Lilly (LLY)
MetricALLY
Dividend Yield (TTM)0.59%0.49%
Dividend Payout Ratio (TTM)19.98%21.71%

Valuation

P/E Ratio (TTM)

Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max
85.34
Q3
43.46
A
34.47
Median
26.69
Q1
13.30
Min
0.07

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

43.95

Max
85.34
LLY
43.95
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and Eli Lilly (LLY) at 13.95 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max
58.18
Q3
25.77
Median
7.30
A
6.68
Q1
3.01
Min
0.01

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.95

Max
58.18
Q3
25.77
LLY
13.95
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both look rich against book: Agilent (A) at 6.69 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 29.96 prices even higher, above its industry range.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max
13.53
A
6.69
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59

LLY

Pharmaceuticals, Biotechnology & Life Sciences industry group

29.96

LLY
29.96
Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Agilent (A) vs. Eli Lilly (LLY): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and Eli Lilly (LLY)
MetricALLY
P/E Ratio (TTM)34.4743.95
P/S Ratio (TTM)6.6813.95
P/B Ratio (MRQ)6.6929.96
Free Cash Flow Yield (TTM)2.15%0.77%